Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00162071 · ClinicalTrials.gov registry record · Phase 2
A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging
A Phase 2 study, sponsored by Forest Laboratories.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00162071 is a Phase 2 study that was terminated before completion, run by Forest Laboratories. The registered enrollment target is 20 participants.
The verdict
NCT00162071, a Phase 2 study, was terminated before completion, sponsored by Forest Laboratories.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 will also be studied.
Interventions
- DRUG apadenoson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00162071
The ClinicalTrials.gov registry entry for NCT00162071 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which apadenoson is the first listed.
NCT00162071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00162071 about?
NCT00162071 is a clinical study titled "A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging". The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 will also be studied.
What is the current status of trial NCT00162071?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2005-07.
What interventions are being tested in trial NCT00162071?
The interventions under investigation include: apadenoson (DRUG).
Who is sponsoring clinical trial NCT00162071?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.